Role of neutrophils in the development and progression of COVID-19

doi:10.16352/j.issn.1001-6325.2023.02.341

Abstract

Abstract: Neutrophils are more innate immune cells found in coronavirus disease in 2019(COVID-19). The accounting of neutrophils and the level of plasma neutrophil extracellular traps(NETs) were positively correlated with the severity of COVID-19. This article reviews the relevant studies of neutrophils, formation and degradation of NETs involved in the pathological process of COVID-19, providing the reference for further studies of pathogenesis and intervention.

Key words: COVID-19, SARS-CoV-2, neutrophil, neutrophil extracellular traps

CLC Number:

R512.99

WANG Liang, SI Ping, SHEN Yongming, CUI Xiaoming. Role of neutrophils in the development and progression of COVID-19[J]. Basic & Clinical Medicine, 2023, 43(2): 341-345.

References 32

[1]	刘力.新型冠状病毒SARS-CoV-2:高致病性及其防治[J].基础医学与临床, 2020, 40:433-439.
[2]	Leliefeld PH, Wessels CM, Leenen LP, et al. The role of neutrophils in immune dysfunction during severe inflammation[J]. Crit Care, 2016, 20:73. doi: 10.1186/s13054-016-1250-4.
[3]	Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China[J]. JAMA, 2020, 323:1061-1069.
[4]	Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J]. Lancet Respir Med, 2020, 8:420-422.
[5]	Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China[J]. JAMA Intern Med, 2020, 180:934-943.
[6]	Barnes BJ, Adrover JM, Baxter-Stoltzfus A, et al. Targeting potential drivers of COVID-19: Neutrophil extra-cellular traps[J]. J Exp Med, 2020, 217:e20200652. doi: 10.1084/jem.20200652.
[7]	Meizlish ML, Pine AB, Bishai JD, et al. A neutrophil activation signature predicts critical illness and mortality in COVID-19[J]. Blood Adv, 2021, 5:1164-1177.
[8]	Sun S, Cai X, Wang H, et al. Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China[J]. Clin Chim Acta, 2020, 507:174-180.
[9]	Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China[J]. Clin Infect Dis, 2020, 71:762-768.
[10]	Liu G, Zhang S, Hu H, et al. The role of neutrophil-lymphocyte ratio and lymphocyte-monocyte ratio in the prognosis of type 2 diabetics with COVID-19[J]. Scott Med J, 2020, 65:154-160.
[11]	Liao MF, Liu Y, Yuan J, et al. The landscape of lung bronchoalveolar immune cells in COVID-19 revealed by single-cell RNA sequencing[J/OL]. medRxiv, 2020 (2020-02-26)[2020-04-03] . https://doi.org/10.1101/2020.02.23.20026690.
[12]	Liu J, Li S, Liu J, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peri-pheral blood of SARS-CoV-2 infected patients[J]. EBioMedicine, 2020, 55:102763. doi: 10.1016/j.ebiom.2020.102763.
[13]	Wang H, Zhang Y, Mo P, et al. Neutrophil to CD4+ lymphocyte ratio as a potential biomarker in predicting virus negative conversion time in COVID-19[J]. Int Immunopharmacol, 2020, 85:106683. doi: 10.1016/j.intimp.2020.106683.
[14]	Veras FP, Pontelli MC, Silva CM, et al. SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology[J]. J Exp Med, 2020, 217:e20201129. doi: 10.1084/jem.20201129.
[15]	Zuo Y, Yalavarthi S, Shi H, et al. Neutrophil extra-cellular traps in COVID-19[J]. JCI Insight, 2020, 5:e138999. doi: 10.1172/jci.insight.138999.
[16]	Colling ME, Kanthi Y. COVID-19-associated coagulopathy: an exploration of mechanisms[J]. Vasc Med, 2020, 25:471-478.
[17]	Wang J, Li Q, Yin Y, et al. Excessive neutrophils and neutrophil extracellular traps in COVID-19[J]. Front Immunol, 2020, 11:2063. doi: 10.3389/fimmu.2020.02063.
[18]	Leppkes M, Knopf J, Naschberger E, et al. Vascular occlusion by neutrophil extracellular traps in COVID-19[J]. EBioMedicine, 2020, 58:102925. doi: 10.1016/j.ebiom.2020.102925.
[19]	Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced host response to SARS-CoV-2 drives develop-ment of COVID-19[J]. Cell, 2020, 181:1036-1045.e9. doi: 10.1016/j.cell.2020.04.026.
[20]	Xiong Y, Liu Y, Cao L, et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients[J]. Emerg Microbes Infect, 2020, 9:761-770.
[21]	Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395:497-506.
[22]	Bhatia M, Zemans RL, Jeyaseelan S. Role of chemokines in the pathogenesis of acute lung injury[J]. Am J Respir Cell Mol Biol, 2012, 46:566-572.
[23]	Abouhashem AS, Singh K, Azzazy HME. Is low alveolar type Ⅱ cell SOD3 in the lungs of elderly linked to the observed severity of COVID-19?[J]. Antioxid Redox Signal, 2020, 33:59-65.
[24]	Cecchini R, Cecchini AL. SARS-CoV-2 infection pathogenesis is related to oxidative stress as a response to aggression[J]. Med Hypotheses, 2020, 143:110102. doi: 10.1016/j.mehy.2020.110102.
[25]	Laforge M, Elbim C, Frère C, et al. Tissue damage from neutrophil-induced oxidative stress in COVID-19[J]. Nat Rev Immunol, 2020, 20:515-516.
[26]	Schönrich G, Raftery MJ, Samstag Y. Devilishly radical NETwork in COVID-19: oxidative stress, neutrophil extracellular traps (NETs), and T cell suppression[J]. Adv Biol Regul, 2020, 77:100741. doi: 10.1016/j.jbior.2020.100741.
[27]	Lee YY, Park HH, Park W, et al. Long-acting nanoparticulate DNase-1 for effective suppression of SARS-CoV-2-mediated neutrophil activities and cytokine storm[J]. Biomaterials, 2021, 267:120389.
[28]	Mohamed MMA, El-Shimy IA, Hadi MA. Neutrophil elastase inhibitors: a potential prophylactic treatment option for SARS-CoV-2-induced respiratory complications?[J]. Crit Care, 2020, 24:311. doi: 10.1186/s13054-020-03023-0.
[29]	Middleton EA, He XY, Denorme F, et al. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome[J]. Blood, 2020, 136:1169-1179.
[30]	Skendros P, Mitsios A, Chrysanthopoulou A, et al. Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis[J]. J Clin Invest, 2020, 130:6151-6157.
[31]	Mastellos DC, Pires da Silva BGP, Fonseca BAL, et al. Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy[J]. Clin Immunol, 2020, 20:108598. doi: 10.1016/j.clim.2020.108598.
[32]	RisitanoAM, MastellosDC, Huber-LangM, et al. Complement as a target in COVID-19？[J]. Nat Rev Immunol, 2020, 20:343-344.